Literature DB >> 22207727

Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women.

Lena Persson1, Peter Henriksson, Eli Westerlund, Outi Hovatta, Bo Angelin, Mats Rudling.   

Abstract

OBJECTIVE: Cholesterol and lipoprotein metabolism display pronounced gender differences. Premenopausal women have lower LDL and higher HDL cholesterol, whereas men display higher synthetic rates of bile acids and cholesterol. The effects of the administration of exogenous hormones to humans and animals indicate that these gender differences can often be explained by estrogens. We evaluated how increased levels of endogenous estrogens modulate cholesterol and lipoprotein metabolism in women. METHODS AND
RESULTS: We studied healthy women during initiation of in vitro fertilization using blood samples obtained when endogenous estrogens were low and high. Cholesterol in VLDL and LDL, but not in HDL, was reduced 20% when estrogens were high. Apolipoprotein B levels decreased 13%. Apolipoprotein A-I and triglyceride levels increased 8% and 37%, respectively, whereas lipoprotein(a) levels were unchanged. Circulating PCSK9, a suppressor of LDL receptors, was reduced 14% when estrogens were high. Serum markers of bile acid and cholesterol synthesis were unaltered. Growth hormone levels increased 3-fold when estrogens were high, whereas insulin-like growth factor-1 and fibroblast growth factor-21 concentrations were unaltered.
CONCLUSION: In women, Apolipoprotein B-containing particles and circulating PCSK9 are reduced when endogenous estrogens are high, indicating that endogenous estrogens induce hepatic LDL receptors partly through a posttranscriptional mechanism. However, estrogens do not stimulate bile acid or cholesterol synthesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207727     DOI: 10.1161/ATVBAHA.111.242461

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  28 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Proprotein convertase subtilisin/kexin type 9 and lipid metabolism.

Authors:  Stefano Spolitu; Wen Dai; John A Zadroga; Lale Ozcan
Journal:  Curr Opin Lipidol       Date:  2019-06       Impact factor: 4.776

Review 3.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

4.  Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.

Authors:  Amy E Levenson; Amy S Shah; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; R Paul Wadwa; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2017-01-17       Impact factor: 4.866

5.  Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.

Authors:  Moumita Ghosh; Cecilia Gälman; Mats Rudling; Bo Angelin
Journal:  J Lipid Res       Date:  2014-12-22       Impact factor: 5.922

Review 6.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

Authors:  Nicola Ferri; Massimiliano Ruscica
Journal:  Endocrine       Date:  2016-04-01       Impact factor: 3.633

7.  Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism.

Authors:  Sara Straniero; Amit Laskar; Christina Savva; Jennifer Härdfeldt; Bo Angelin; Mats Rudling
Journal:  J Lipid Res       Date:  2020-02-21       Impact factor: 5.922

8.  Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women.

Authors:  Gordon I Smith; Dominic N Reeds; Adewole L Okunade; Bruce W Patterson; Bettina Mittendorfer
Journal:  J Clin Endocrinol Metab       Date:  2014-04-02       Impact factor: 5.958

9.  The α' subunit of β-conglycinin and the A1-5 subunits of glycinin are not essential for many hypolipidemic actions of dietary soy proteins in rats.

Authors:  Qixuan Chen; Carla Wood; Christine Gagnon; Elroy R Cober; Judith A Frégeau-Reid; Stephen Gleddie; Chao Wu Xiao
Journal:  Eur J Nutr       Date:  2013-11-26       Impact factor: 5.614

10.  Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.

Authors:  Amy E Levenson; Mary E Haas; Ji Miao; Rebecca J Brown; Sarah D de Ferranti; Ranganath Muniyappa; Sudha B Biddinger
Journal:  Endocrinology       Date:  2016-01-29       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.